12:14 PM EST - Thallion Pharmaceuticals Inc. : announced that the Independent Data Monitoring Committee (IDMC) for the Company's Phase II SHIGATEC trial has completed a planned safety analysis and recommends that the trial continue as per the protocol. This scheduled review by the IDMC occurred after the treatment and 56-day follow-up of the 22 patients that received the low dose treatment (1 mg/kg/dose) in the first cohort of the trial. The purpose of the IDMC is to provide objective, independent safety monitoring of the SHIGATEC trial, a study evaluating Shigamabs(R) as a treatment for Shiga toxin-producing E. coli (STEC) infection. Thallion Pharmaceuticals Inc.
shares T.TLN are trading up $0.01 at $0.15.
